Answer
Women must not breastfeed during treatment with inotuzumab ozogamicin and for at least 2 months after the final dose because of the potential for adverse reactions in breastfed children.
Sources for this answer
- BESPONSA 1 mg powder for concentrate for solution for infusionPfizer Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 11Document updated
Sources checked